CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), targeting programmed cell death protein 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1), opened a novel landscape of treatment algorithms in advanced non‐small‐cell lung cancer (NSCLC).1